Specific inhibitors of p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways block inducible nitric oxide synthase and tumor necrosis factor accumulation in murine macrophages stimulated with lipopolysaccharide and interferon-γ

Journal of Infectious Diseases

Volumn 179, Issue 4, 1999, Pages 939-944

  Ajizian, Samuel J ^a   English, B Keith ^b   Meals, Elizabeth A ^b  

^a LE BONHEUR CHILDREN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ENZYME INHIBITOR; GAMMA INTERFERON; LIPOPOLYSACCHARIDE; NITRIC OXIDE SYNTHASE; PROTEIN KINASE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ARTICLE; ENZYME ACTIVATION; ENZYME ANALYSIS; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SYNTHESIS; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; WESTERN BLOTTING;

CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONOIDS; HUMANS; IMIDAZOLES; INTERFERON TYPE II; LIPOPOLYSACCHARIDES; MACROPHAGES; MITOGEN-ACTIVATED PROTEIN KINASES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032925361     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314659     Document Type: Article

References (25)

1. Fang F. Mechanisms of nitric oxide-related antimicrobial activity. J Clin Invest 1997;99:2818-25.
2. Evans T, Carpenter A, Kinderman H, Cohen J. Evidence of increased nitric oxide production in patients with sepsis syndrome. Circ Shock 1993;41:77-81.
3. Nathan C. Inducible nitric oxide synthase: what difference does it make? J Clin Invest 1997;100:2417-23.
4. Michel T, Feron O. Nitric oxide synthases: which, where, how, and why? J Clin Invest 1997;100:2146-52.
5. Beutler B. The biology of cachectin/TNF a primary mediator of the host response. Annu Rev Immunol 1989;7:625-55.
6. Gardlund B, Sjolin J, Nilsson A, Roll M, Wickerts CJ, Wretlind B. Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity. J Infect Dis 1995;172:296-301.
7. Boulton T, Nye SH, Robbins DJ, et al. ERKs: a family of protein-serine/ threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 1991;65:663-675.
8. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739-46.
9. Kyriakis JM, Banjeree P, Nikolakaki E, et al. The stress activated protein kinase subfamily of c-Jun kinases. Nature 1994;369:156-60.
10. Weinstein SL, Sanghera JS, Lemke K, DeFranco AL, Pelech SL. Bacterial lipopolysaccharide induces tyrosine phosphorylation and activation of mitogen-activated protein kinases in macrophages. J Biol Chem 1992;267:14955-62.
11. 2-terminal kinase mitogen-activated protein kinases by bacterial peptidoglycan. J Infect Dis 1996;174:777-85.
12. Lee JC, Young PR. Role of CSBP/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. J Leukoc Biol 1996;59:152-7.
13. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995;92:7686-9.
14. Swantek J, Cobb MH, Geppert T. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNFα) translation: glucocorticoids inhibit TNFα translation by blocking JNK/SAPK. Mol Cell Biol 1997;17:6274-82.
15. Trotta R, Kanakaraj P, Perussia B. FcγR-dependent mitogen-activated protein kinase activation in leukocytes: a common signal transduction event necessary for expression of TNF-α and early activation genes. J Exp Med 1996;184:1027-35.
16. Bhat NR, Zhang P, Lee JC, Hogan EL. Extracellular signal-regulated kinase and p38 subgroups of mitogen-activated protein kinases regulate inducible nitric oxide synthase and tumor necrosis-α gene expression in endotoxin-stimulated primary glial cultures. J Neurosci 1998;18:1633-41.
17. Da Silva J, Pierrat B, Mary JL, Lesslauer W. Blockade of p38 mitogen-activated protein kinase pathway inhibits inducible nitric-oxide synthase expression in mouse astrocytes. J Biol Chem 1997;272:28373-80.
18. Badger AM, Cook MN, Lark MW, et al. SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes. J Immunol 1998;161:467-73.
19. Caivano M. Role of MAP kinase cascades in inducing arginine transporters and nitric oxide synthetase in RAW264 macrophages. FEBS Lett 1998;429:249-53.
20. Orlicek SL, Meals E. English BK. Differential effects of tyrosine kinase inhibitors on tumor necrosis factor (TNF) and nitric oxide production by murine macrophages. J Infect Dis 1996;174:638-42.
21. Hierholzer C, Harbrecht B, Menezes JM, et al. Essential role of induced nitric oxide in the initiation of the inflammatory response after hemorrhagic shock. J Exp Med 1998;187:917-28.
22. Thiemermann C. Nitric oxide and septic shock. Gen Pharmacol 1997;29:159-66.
23. Avontuur J, Nolthenius R, Bodegom J, Bruining H. Prolonged inhibition of nitric oxide synthesis in severe septic shock: a clinical study. Crit Care Med 1998;26:660-7.
24. Liaudet L, Rosselet A, Schaller MD, Markert M, Perret C, Feihl F. Non-selective versus selective inhibition of inducible nitric oxide synthase in experimental endoloxic shock. J Infect Dis 1998;177:127-32.
25. Badger A, Bradbeer J, Votta B, Lee JC, Adams J, Griswold D. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock, and immune function. J Pharmacol Exp Ther 1996;279:1453-61.